Biosimilar Week is an integral component of a comprehensive 3-year education program focusing on the appropriate use of biosimilar medicines, developed collaboratively by experts across medical specialities, government and the medicines industry. The Program is coordinated by GBMA Education and funded by the Australian Government through the Biosimilar Educational Grant, announced in April 2018.
Biosimilar Week will commence with an official announcement from the Hon Greg Hunt, Minister of Health, highlighting the critical role that biosimilar medicines play in the future of a sustainable healthcare system in Australia.
Biological medicines are pharmaceutical products that contain one or more active substances derived from living cells or organisms1. A biosimilar medicine is a highly similar version of an already registered biological medicine (the reference biological medicine)1. The regulatory conditions required for biosimilar medicines in Australia mean that a biosimilar medicine approved for use in the Australian market can be said to have no clinically meaningful difference and be therapeutically equivalent to its reference biological medicine1,2.References:
|March 7-10||APP 2019 conference†|
|April 29 - May 3||Biosimilar Week†|
|August - September||National Multidisciplinary Event†|
|This event will be an opportunity for healthcare professionals across various specialties to share the latest updates and insights on Biosimilar Medicine|
|September - Ongoing||Hospital-based education sessions†|
|State based hospital education sessions at various teaching hospitals nationwide|
|July - November||Conference attendance and education sessions†|
|GBMA Education will continue their presence at various education sessions and conferences throughout 2019 spanning the various pharmacy, GP and specialty areas|
† These are the confirmed events for the remainder of 2019, GBMA Education will communicate more broadly on the specific activities as we move throughout the year.
The quarterly literature reviews provide an update to the comprehensive literature search previously conducted on behalf of the Department of Health. To inform the activities related to GBMA Education’s Biosimilar Education Grant these reviews examine all international and Australian clinical, academic and policy journals in relation to biosimilar medicines.
The reviews are conducted with an emphasis on ensuring that the evidence is up-to-date in the following key topic areas: